Please login to the form below

Not currently logged in
Email:
Password:

Allergy Therapeutics

This page shows the latest Allergy Therapeutics news and features for those working in and with pharma, biotech and healthcare.

ALK-Abello debuts its birch pollen allergy therapy in Germany

ALK-Abello debuts its birch pollen allergy therapy in Germany

Birch trees are one of the most common causes of tree pollen allergy. ... added. The launch comes after a potential rival to Itulazax from UK-based Allergy Therapeutics  flunked a phase 3 trial, setting the programme back by several months or more and

Latest news

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... The two are being held up as potential life-saving therapies for the estimated six million people with this

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major word markets could be worth $4.5bn in 2027.

  • Aimmune preps EU filing for peanut allergy immunotherapy Aimmune preps EU filing for peanut allergy immunotherapy

    its first attempt - as well other rivals including the UK’s Allergy Therapeutics whose candidate is still in early development. ... 8bn a year, given that there are around 1.5 million people with peanut allergy apiece in the US and Europe.

  • Allergy Tx hit hard as birch pollen product stumbles Allergy Tx hit hard as birch pollen product stumbles

    Allergy Therapeutics had pitched 2019 as a pivotal year for its product pipeline, but has suffered a setback before the first quarter has come to an end. ... the first product of its kind in the $2bn US allergy market and a phase 1 peanut allergy

  • Positive mid-stage trial gives Allergy’s investors some welcome relief Positive mid-stage trial gives Allergy’s investors some welcome relief

    Its grass pollen vaccine showed a “highly significant” dose response. Allergy Therapeutics’ long-stalled efforts to develop a grass pollen allergy candidate finally seem to have lurched into motion, with a ... This study represents a major

More from news
Approximately 4 fully matching, plus 20 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics